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OBJECTIVES: To inform a multiple technology appraisal to be conducted by the 
National Institute for Health and Care Excellence on the use of agents that inhibit 
sodium-glucose co-transporter 2 (SGLT2), canagliflozin was assessed as monother-
apy treatment for T2DM. METHODS: A systematic literature review identified 36 
trials, which were used to perform a Bayesian NMA to estimate the relative efficacy 
(HbA1c, weight, and systolic blood pressure [SBP]) of canagliflozin monotherapy at 
26±4 weeks compared to dipeptidyl peptidase-4 inhibitors (DPP-4s), sulphonylurea, 
pioglitazone, and SGLT2 inhibitors. Networks of evidence had treatment- and dose-
specific nodes for DPP-4s, pioglitazone, and SGLT2 inhibitors. Relative efficacy was 
evaluated based on absolute differences and Bayesian probabilities (P), where 30%< 
P > 70% were chosen to indicate a smaller and larger effect, respectively. RESULTS: 
Results presented here focus on comparisons to the most relevant anti-hypergly-
caemic therapies in the UK; sitagliptin, gliclazide, pioglitazone, dapagliflozin 10mg, 
and empagliflozin 10mg/25mg. Canagliflozin 300mg was associated with greater 
reductions in HbA1c (Δ –0.29 to –0.52) versus all comparators. Canagliflozin 100mg 
conferred reductions in HbA1c at least as large as other comparator (Δ –0.03 to 
–0.26). Canagliflozin was associated with larger reductions in weight (kg) versus 
all comparators (Δ –0.41 to –7.03), except for canagliflozin 100mg versus empagli-
flozin 25mg, where the reduction was similar (Δ –0.19). Canagliflozin 300mg was 
associated with larger reductions in SBP (Δ –1.06 to –6.29) versus all comparators. 
Canagliflozin 100mg was associated with greater reductions in SBP versus empagli-
flozin 10mg, pioglitazone, and sitagliptin (Δ –1.11 to –4.60) and provided comparable 
reductions in SBP versus dapagliflozin 10mg and empagliflozin 25mg (Δ 0.65 and 
–0.31). CONCLUSIONS: The results of this NMA suggest that canagliflozin 300mg 
monotherapy was associated with consistently greater HbA1c and SBP reductions 
versus all comparators, relevant to UK prescribing habits; while canagliflozin 100mg 
was at least similar. Weight reductions were larger for both doses of canagliflozin 
compared to all comparators.
PDB23
clinical evaluation of shuDDha guggulu in hyPothyroiDisM 
Patients
Suvarna H.P.1, Acharya S.2, Nagappa A.N.3
1Muniyal College of Ayurveda, Manipal, India, 2Muniyal Institute of Ayurveda Medical sciences, 
Manipal, India, 3Department of Pharmacy Management, Manipal College of Pharmaceutical 
Sciences, Manipal University, Manipal, India
OBJECTIVES: To evaluate the clinical effectiveness of Shuddha Guggulu 
(Commiphora mukul) in Hypothyroidism patients. METHODS: A randomized sin-
gle blind clinical study with pretest and posttest design was adopted, where the 
patients were given treatment with specific duration with follow up. In total 379 
patients were selected from the OPD of Muniyal Institute of Ayurvedic Medical 
Sciences Manipal enrolled for the present study out of which 32 were dropped out 
from the study. Thyroid function test, Routine hematological, bio-chemical and 
urine analysis were recorded. The main Signs and Symptoms weight and height 
ratio (BMI – Body Mass Index), Joint pain, Muscle cramps and Tiredness were taken 
for assessment as symptoms grade parameters. Elevation of value of T3 and T4 to 
normal range, decline the TSH value to normal range and Blood Cholesterol also 
taken for the assessment as Laboratory parameters. Data obtained from the above 
mentioned study was statistically analyzed by using the Z test. RESULTS: Shuddha 
Guggulu provided 55.55%. relief in Joint pain and 23.68%, relief in Tiredness which 
were statistically highly significant result p< 0.001, where as in Body mass index, 
Muscle cramps and Anorexia provided 2.2%, 45.45% and 38.71% relief respectively 
which were also statistically highly significant result p< 0.005. Shuddha Guggulu 
provided 23.73% relief in Triiodothyronine (T3), 26.72% relief in Thyroxin (T4), 45.86% 
relief in Thyroid Stimulating Hormone (TSH) and 10.47% relief in Blood Cholesterol 
which were statistically showing highly significant result P < 0.001. CONCLUSIONS: 
Shuddha guggulu appears to be beneficial in those who have metabolic syndrome 
which includes high blood Cholesterol, obesity, and an overall inflammatory pattern. 
Whether it stimulates thyroid function in every condition is still being evaluated.
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OBJECTIVES: To evaluate the efficacy and safety of canagliflozin in combination 
therapy among patients with inadequately controlled type 2 diabetes mellitus 
(T2DM). METHODS: Two review authors independently searched for the relevant 
randomized and controlled clinical trials from the Cochrane Central Register of 
Controlled Trials, MEDLINE, EMBASE, IndMed, LILACS, and clinical trials regis-
try www.clinicaltrials.gov. Primary outcomes for this review included: change in 
HbA1c levels, fasting plasma glucose (FPG) levels and risk of occurrence of urinary 
tract infections; secondary outcomes included mean change in body weight at 26 
weeks and risk of occurrence of genital mycotic infections among both males and 
females separately. We combined results using mean difference (MD) for continu-
ous data, and risk ratio (RR) for dichotomous data. RESULTS: Of the 124 identified 
reports, nine RCTs were included in qualitative analysis and four RCTs with 1568 
participants were eligible for the meta-analysis. All included studies compared 
canagliflozin 300 mg once daily with placebo. We judged that most of the studies 
had low risk of bias or unclear risk of bias in five major domains. Canagliflozin led 
to a significant decrease in HbA1c levels (MD -0.77 [95% CI -0.90, -0.64, p< 0.001]); 
of type 2 diabetes mellitus and cardiovascular events. In order to evaluate the efficacy 
and safety of using metformin to treat prediabetes compared with intensive lifestyle 
intervention, a systematic review was performed. METHODS: Structured searches 
were conducted in the bibliographic databases PubMed/MEDLINE, Cochrane Library, 
LILACS, and CRD until 02/13/2014. Selection criteria included randomized clinical 
trials evaluating the use of metformin compared with intensive lifestyle intervention 
in the treatment of patients with prediabetes. Two reviewers independently scanned 
titles and abstracts for potentially eligible trials. RESULTS: Ramachandran et al. 
showed that intensive lifestyle intervention and metformin reduce the incidence of 
type 2 diabetes mellitus in a native Indian population with impaired glucose tolerance, 
but did not demonstrate additional benefit of the strategy using the combination of 
metformin plus intensive lifestyle intervention in reducing the incidence of type 2 
diabetes mellitus. Knowler et al. have shown that intensive lifestyle intervention and 
metformin were both effective in reducing the incidence of diabetes, but the intensive 
lifestyle intervention was more effective than the use of metformin. CONCLUSIONS: 
Either metformin or a program of intensive lifestyle intervention for the treatment of 
patients with prediabetes are clinically relevant with significant results. The clinical 
effectiveness of each intervention may vary according to the protocol of care and 
dose of medication used. Treatment choices should balance the benefits and adverse 
effects of each method and integrate patient’s personal values, as well as considering 
the feasibility of each intervention according to local characteristics. Further research 
is strongly recommended.
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OBJECTIVES: An extended-release (XR) formulation of metformin has been designed 
to optimize drug delivery with the same antihyperglycemic efficacy as metformin 
immediate-release (IR). A systematic review was conducted to assess efficacy, 
safety and treatment adherence of metformin XR in prediabetes or DM-2 manage-
ment. METHODS: Electronic searches were performed in MEDLINE, LILACS, EMBASE, 
CRD, among others, until May 2014. Search terms included “diabetes mellitus type 
2” and “metformin XR” or “glucophage XR” via MESH controlled vocabulary for the 
Pubmed database and adapted for other databases. Were included: meta-analyses, 
systematic reviews, randomized clinical trials and observational studies with infor-
mation on patients using metformin XR for prediabetes or DM-2 treatment. Two 
reviewers performed the search RESULTS: Nine studies were included and 6,316 
patients were identified. Eight studies evaluated efficacy and all of them safety of 
metformin XR compared with metformin IR or placebo. One study evaluated treat-
ment adherence. Five studies showed a reduction in glycated hemoglobin (HbA1C) 
when compared with placebo, metformin IR or baseline values, and four presented 
no significant differences between metformin XR and metformin IR. Three studies 
found a decrease in fasting plasma glucose and two showed no statistical differ-
ence between metformin IR and XR. Metformin XR showed a beneficial effect on 
lipid profile, however is not possible to affirm superiority compared to metformin 
IR. Metformin XR effect on weight variation seems inconclusive. Regarding safety, 
when compared with placebo, metformin XR may cause dizziness, abdominal pain, 
diarrhea, nausea/vomiting, and urinary tract infection, but is well tolerated by most 
patients without further complications. When compared with metformin IR, all 
studies showed that metformin XR causes less AEs and greater treatment adher-
ence. CONCLUSIONS: In summary, metformin XR showed better or at least similar 
efficacy, and an improved adherence and safety when compared with metformin 
IR. This profile may indicate an important improvement for DM-2 management.
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OBJECTIVES: To assess the efficacy and safety of insulin add-on therapies for Type 
2 diabetes, when insulin with up to two oral anti-diabetes drugs (OADs) does not 
provide adequate glycaemic control. METHODS: A systematic review was conducted 
(MEDLINE, EMBASE and CENTRAL) to identify relevant randomised controlled tri-
als for treatments licensed in the EU at the time of the literature search (July 2013). 
Relative treatment effects were estimated using Bayesian network meta-analysis 
(NMA) via WinBUGs. RESULTS: Seven studies were suitable for inclusion in this 
subgroup analysis at 24 (+/- 6) weeks follow-up and drug classes included were 
SGLT2 inhibitors (dapagliflozin), GLP1 analogues, and DPP4 inhibitors. Trial eligibility 
criteria were broadly similar in terms of qualifying HbA1c, BMI and age. Six stud-
ies had a stable insulin background. The GLP1 study had a ‘treat-to-target’ insulin 
background. Based on the basecase random-effects NMA, all classes of treatment 
resulted in statistically significantly lower HbA1c at follow-up compared to placebo 
(based on the 95% credible interval [CrI]): SGLT2i -0.66 [95%CrI -1.23, -0.09]; GLP1 -0.51 
[95%CrI -0.92, -0.09]; and DPP4 -0.58 [95%CrI -0.87, -0.30]. SGLT2i and GLP1s resulted 
in significantly lower weight at follow-up compared to placebo (-1.86 kg [95%CrI 
-3.64, -0.07] and -1.88kg; [95%CrI -3.27, -0.67] respectively); DPP4i did not result in a 
significant difference in weight compared to placebo (0.06 kg [-0.76, 0.96]). The odds 
of hypoglycaemia for all classes of add-on treatment were not significantly differ-
ent to placebo. CONCLUSIONS: After 24 weeks of treatment SGLT2i when added 
to insulin (+OADs) is non-inferior to DPP4i and GLP1s in terms of HbA1c reduction 
without increasing the risk of hypoglycemia. However, SGLT2i and GLP1s have an 
added benefit of weight loss.
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sample t-test to evaluate glycemic control associated with CANA. RESULTS: A total 
of 9,805 CANA users were identified, among which 6,571 (67%) were in the CANA100 
group (mean age: 59; 48% female; 75% white; mean Charlson Comorbidity Index 
[CCI]: 1.8; mean Diabetes Complications Severity Index [DCSI]: 0.9) and 3,234 (33%) 
were in the CANA300 group (mean age: 57; 44% female; 75% white; mean CCI: 1.6; 
mean DCSI: 0.8). Before the index date, 98% and 97% of patients were prescribed 
≥ 1 antihyperglycemic agent, with a mean number of 5.6 and 5.5 antihyperglyce-
mic agents per patient in the CANA100 and CANA300 groups, respectively. In the 
6 months following CANA initiation, mean HbA1c values decreased from 8.4% to 
7.9% (p< 0.0001) among CANA100 patients and from 8.5% to 7.8% (p< 0.0001) among 
CANA300 patients. CONCLUSIONS: Patients treated with CANA in the real-world 
setting often received multiple prior diabetes treatments and had uncontrolled 
HbA1c levels. Patients taking CANA significantly improved their HbA1c values, with 
numerically greater improvement in those with CANA 300mg.
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OBJECTIVES: Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor recently 
approved for T2DM treatment, which does not require dose adjustment in 
patients with renal or hepatic impairment. The patterns of treatment adher-
ence among patients initiating linagliptin in routine care settings are largely 
unknown. METHODS: Within a large, nationwide US health insurance database 
(Optum Clinformatics), we identified T2DM patients ≥ 18 years initiating linagliptin 
or other NIDMs from May 2011 through June 2012. Patients were followed for adher-
ence measures for up to 12 months. Findings were replicated in a propensity score 
(PS)-matched population and in another US commercial health insurance database 
(MarketScan). RESULTS: Of 155,345 T2DM patients initiating a NIDM, 46.8% initiated 
metformin, followed by sulfonylureas (21.8%), and sitagliptin (11.9%). Linagliptin was 
initiated by 2,820 patients (1.8%). Linagliptin and saxagliptin initiators had the high-
est proportion of days covered [PDC] (77.5% and 75.8%, respectively) and medication 
possession ratio [MPR] (0.67 and 0.66). Similarly, compared to initiators of other 
agents, these patients less frequently filled only one dispensing of their medica-
tion [1DISP] (15.0% for linagliptin and 15.7% for saxagliptin), and more persisted on 
therapy at 12 months [P12] (51.5% and 49.8%). Metformin initiators had PDC = 70.4%, 
MPR = 0.57, 1DISP = 23.0%, and P12 = 35.5%. The lowest adherence measures were 
observed among initiators of meglitinides (PDC 64.0%; MPR 0.46; 1DISP 32.4%; P12 
22.6%), glitazones (PDC 68.8%; MPR 0.51; 1DISP 30.2%; P12 28.4%) and GLP-1 receptor 
agonists (PDC 68.3%; MPR 0.54; 1DISP 23.3%; P12 33.6%). These patterns of adherence 
were similar after PS-matching and in MarketScan data, suggesting differences in 
adherence were not due to patient or health insurer characteristics. CONCLUSIONS: 
Compared to other NIDMs, patients initiating linagliptin (along with saxagliptin) 
exhibit greater adherence to therapy. The observed patterns of adherence are not 
likely to be due to patient or health insurer characteristics.
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OBJECTIVES: Chronic activation of the pathological arm of the renin angiotensin 
system (RAS) contributes to lung fibrosis, chronic inflammation, impaired immune 
function and oxidative stress in type 2 diabetic (T2D) patients. Studies have shown 
that diabetic patients treated with angiotensin-converting-enzyme (ACE) inhibitors 
or angiotensin II receptor blockers (ARBs) achieve a reduction in all-cause mortal-
ity. Our objective is to determine if RAS-modifying medications have a beneficial 
impact on lung health and immunity in T2D patients. METHODS: A retrospec-
tive analysis was conducted using claims data from a US commercial insurance 
company. The study groups consisted of T2D patients taking either: ACE inhibi-
tors, ARBs, control [diuretics or calcium-channel blockers (CCBs)], or combination 
drugs (ACE inhibitors/diuretics, ARBs/diuretics, ACE inhibitors/CCBs, ARBs/CCBs). 
Logistic regression analyses were performed to estimate the association between 
exposure to each treatment and the incidence of respiratory complications: pneu-
monia and influenza (PNIN) or chronic obstructive pulmonary disease and allied 
conditions (COPDAC). RESULTS: A total of 171,857 patients were identified. During 
the 4.5 year of follow-up, patients treated with ACE inhibitors had lower incidence 
of PNIN [8.84%, odds ratio (OR) 0.91, 95% CI 0.86-0.94] or COPDAC (17.1%, OR 0.86, 
95% CI 0.84-0.90), compared to patients treated with control drugs (9.93% and 19.71% 
respectively). ARBs patients also exhibited a lower rate of PNIN (8.89%, OR 0.91, 95% 
CI 0.86-0.97) and COPDAC (17.1%, OR 0.86, 95% CI 0.82-0.90) compared to control. 
Patients treated with combination drugs exhibited the lowest incidence of PNIN 
(8.14%, OR 0.86, 95% CI 0.82-0.91) and COPDAC (16.15%, OR 0.82, 95% CI 0.80-0.86) 
relative to control patients. CONCLUSIONS: Preliminary results suggest that there is 
a measurable benefit from RAS-modifying medications on pulmonary health in T2D 
patients. There are no notable differences in patients treated with either ACE inhibi-
tors or ARBs. Further, there may also be added benefit of using combination therapy.
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FPG levels (MD -2.17 [CI 95% -2.44, 1.91, p< 0.001]) and body weight (MD-2.91 [95% 
CI -3.50, -2.32]) after 26 weeks as compared to placebo. The risk of occurrence of 
urinary tract infections (RR 1.25 [95% CI 0.80, 1.94]), genital mycotic infections 
among males (RR 8.73 [CI 95% 2.07, 36.72, p= 0.003]) and females (RR 4.37 [CI 95% 
2.03, 9.38, p= 0.0002]) was higher in the canagliflozin arm as compared to placebo 
arm. CONCLUSIONS: Canagliflozin significantly decreases HbA1c, FPG levels 
and body weight while increasing the risk of urinary tract infections and genital 
mycotic infections as compared to placebo among patients with inadequately 
controlled T2DM.
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OBJECTIVES: To examine the relationship between different anti-diabetic thera-
pies (DPP-4, metformin and sulfonylureas) and risk of acute pancreatitis among 
type 2 diabetic patients in Taiwan, and explore each drug’s dose-response relation-
ship. METHODS: We derived a nationwide retrospective cohort of patients with 
type 2 diabetes in Taiwan. The inclusion criteria are adult diabetic patients with 
continuous baseline enrollment, new users of the studied drugs, and without miss-
ing demographics. There were 4,113/101,498/44,772 DPP-4/Metformin/Sulfonylurea 
users. Adjusted hazards ratios for pancreatitis associated with DPP-4, derived from 
Cox Proportional Hazard models with propensity score weighting, were estimated; 
dose-response analyses were also conducted. RESULTS: DPP-4 was statistically 
significantly associated with a decreased risk of acute pancreatitis compared to 
sulfonylureas (adjusted HR: 0.36, 95% CI: 0.17-0.75) but not metformin (adjusted HR: 
0.67, 95% CI: 0.32-1.41); metformin was statistically significantly associated with a 
lower risk of pancreatitis than sulfonylurea (adjusted HR: 0. 53; 95% CI, 0.37-0.76). 
In addition, low-dose metformin was statistically significantly associated with a 
lower risk of pancreatitis compared to high-dose metformin (HR: 0.65; 95% CI, 0.44-
0.97). CONCLUSIONS: Our findings suggest that sulfonylureas may potentially be 
associated with an increased risk of pancreatitis compared to DPP-4 or metformin. 
This population-based cohort study extends the previous evidence in an ethnic 
Chinese type 2 diabetic cohort. Studies with longer follow up, larger sample sizes 
and more precise capture of confounders may be needed to determine the risk of 
pancreatitis associated with Incretin based therapies.
PDB26
real-worlD aDherence in MeDicare Patients with tyPe 2 DiaBetes 
Mellitus (t2DM) for exenatiDe qw anD liraglutiDe qD
Tarr A1, Nguyen H2, Dufour R1, Bullano M2
1Comprehensive Health Insights, Inc, Louisville, KY, USA, 2AstraZeneca, Fort washington, PA, USA
OBJECTIVES: Real-world evidence on adherence to glucagon-like peptide-1 recep-
tor agonist (GLP-1RA) in elderly or disabled patients is limited. Patient adherence to 
an antidiabetic regimen is a clinical challenge when considering the medical com-
plexities of T2DM in elderly patients and other comorbidities associated with aging. 
GLP-1RA therapies such as exenatide once weekly (QW) and liraglutide once daily 
(QD) are an increasingly used class of drugs with proven efficacy and tolerability. 
The current study examined adherence to medication in patients age ≥ 65 years 
with T2DM initiating a GLP-1RA. METHODS: The study used medical and pharmacy 
claims between 2010 and 2013 for Medicare members in a US health plan diagnosed 
with T2DM and were new initiators of either exenatide QW (n= 537) or liraglutide QD 
(n= 3673) during that time frame and were continuously enrolled for 6 months pre- 
and post-index. Proportion of Days Covered (PDC) ≥ 80% was used to determine post-
index adherence. Logistic regression models controlled for baseline demographics, 
comorbidities and T2DM treatments. RESULTS: A significantly higher percentage of 
patients on exenatide QW had a PDC ≥ 80% (43.2%) vs liraglutide QD (35.0%, χ 2, p< .01). 
Adjusted results indicated patients on liraglutide QD were 20.1% (p< .01) less likely to 
be adherent than patients on exenatide QW. Two other significant factors associated 
with lower adherence were: evidence for cardiovascular disease and plan type. The 
mean proportion of days covered showed patients on exenatide QW had a slightly 
higher medication possession rate of GLP1-RA compared with patients on liraglutide 
QD: 63.5% vs. 61.5% (ns). CONCLUSIONS: Results from this retrospective study sug-
gest that overall adherence to GLP-1RAs was low, but was better with exenatide QW. 
Patients 65 years and older treated with exenatide QW had a significantly higher 
adherence rate compared to liraglutide QD. Further research is needed to validate 
these findings in other patient populations.
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OBJECTIVES: Canagliflozin (CANA), an agent that inhibits sodium glucose co-
transporter 2, has been shown to improve glycemic control in patients with T2DM 
in clinical trials. The current study described the early clinical characteristics and 
glycemic control of T2DM patients receiving different doses of CANA following 
approval of CANA in a real-world setting. METHODS: Adults with ≥ 1 diagnosis for 
T2DM and ≥ 6 months of clinical activity before first CANA prescription (index) were 
identified in the Cegedim Strategic Data US electronic medical records database, in 
which 60% of contributors are primary care providers. Patients were stratified by 
their first CANA daily dose (100mg [CANA100] or 300mg [CANA300]) observed in the 
database. Patients’ clinical characteristics were assessed descriptively and HbA1c 
levels at baseline and 6 months after the index date were compared using paired 
